166 related articles for article (PubMed ID: 28400260)
21. Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.
Ballon JS; Pajvani UB; Mayer LE; Freyberg Z; Freyberg R; Contreras I; Rosenbaum M; Leibel RL; Lieberman JA
J Psychopharmacol; 2018 May; 32(5):533-540. PubMed ID: 29444618
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Beebe KL; Block T; Debattista C; Blasey C; Belanoff JK
Behav Brain Res; 2006 Aug; 171(2):225-9. PubMed ID: 16782211
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats.
Zhang Q; Lian J; He M; Deng C; Wang H; Huang XF
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():172-80. PubMed ID: 24548587
[TBL] [Abstract][Full Text] [Related]
24. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.
Smith GC; Vickers MH; Shepherd PR
Arch Physiol Biochem; 2011 Oct; 117(4):241-9. PubMed ID: 21671852
[TBL] [Abstract][Full Text] [Related]
25. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.
Minet-Ringuet J; Even PC; Valet P; Carpéné C; Visentin V; Prévot D; Daviaud D; Quignard-Boulange A; Tomé D; de Beaurepaire R
Mol Psychiatry; 2007 Jun; 12(6):562-71. PubMed ID: 17211438
[TBL] [Abstract][Full Text] [Related]
26. Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model.
Horska K; Kucera J; Drazanova E; Kuzminova G; Amchova P; Hrickova M; Ruda-Kucerova J; Skrede S
Biomed Pharmacother; 2024 Jul; 176():116763. PubMed ID: 38805968
[TBL] [Abstract][Full Text] [Related]
27. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.
Vidarsdottir S; Vlug P; Roelfsema F; Frölich M; Pijl H
J Clin Psychiatry; 2010 Sep; 71(9):1205-11. PubMed ID: 20441717
[TBL] [Abstract][Full Text] [Related]
28. A parametric analysis of olanzapine-induced weight gain in female rats.
Cooper GD; Pickavance LC; Wilding JP; Halford JC; Goudie AJ
Psychopharmacology (Berl); 2005 Aug; 181(1):80-9. PubMed ID: 15778884
[TBL] [Abstract][Full Text] [Related]
29. Insulin resistance following continuous, chronic olanzapine treatment: an animal model.
Chintoh AF; Mann SW; Lam TK; Giacca A; Remington G
Schizophr Res; 2008 Sep; 104(1-3):23-30. PubMed ID: 18675538
[TBL] [Abstract][Full Text] [Related]
30. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.
Patil BM; Kulkarni NM; Unger BS
Eur J Pharmacol; 2006 Dec; 551(1-3):112-5. PubMed ID: 17046744
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80.
Richards M; Chiba S; Ninomiya M; Wakabayasi C; Kunugi H
Pharmacopsychiatry; 2013 Nov; 46(7):267-73. PubMed ID: 24105080
[TBL] [Abstract][Full Text] [Related]
32. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
Deng C; Lian J; Pai N; Huang XF
J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490
[TBL] [Abstract][Full Text] [Related]
33. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
[TBL] [Abstract][Full Text] [Related]
34. Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.
Victoriano M; Hermier D; Even PC; Fromentin G; Huneau JF; Tomé D; de Beaurepaire R
Psychopharmacology (Berl); 2009 Sep; 206(1):167-76. PubMed ID: 19572122
[TBL] [Abstract][Full Text] [Related]
35. Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats.
Shobo M; Yamada H; Koakutsu A; Hamada N; Fujii M; Harada K; Ni K; Matsuoka N
Life Sci; 2011 Apr; 88(17-18):761-5. PubMed ID: 21356217
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.
Victoriano M; de Beaurepaire R; Naour N; Guerre-Millo M; Quignard-Boulangé A; Huneau JF; Mathé V; Tomé D; Hermier D
Brain Res; 2010 Sep; 1350():167-75. PubMed ID: 20570665
[TBL] [Abstract][Full Text] [Related]
37. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Hoffmann VP; Case M; Jacobson JG
J Clin Psychiatry; 2012 Feb; 73(2):216-23. PubMed ID: 21672497
[TBL] [Abstract][Full Text] [Related]
38. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.
Lord CC; Wyler SC; Wan R; Castorena CM; Ahmed N; Mathew D; Lee S; Liu C; Elmquist JK
J Clin Invest; 2017 Sep; 127(9):3402-3406. PubMed ID: 28805659
[TBL] [Abstract][Full Text] [Related]
39. Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding.
Castellani LN; Wilkin J; Abela AR; Benarroch L; Ahasan Z; Teo C; Wilson V; Kowalchuk C; Giacca A; Remington GJ; Hahn MK
Psychoneuroendocrinology; 2018 Dec; 98():127-130. PubMed ID: 30142549
[TBL] [Abstract][Full Text] [Related]
40. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.
Davey KJ; O'Mahony SM; Schellekens H; O'Sullivan O; Bienenstock J; Cotter PD; Dinan TG; Cryan JF
Psychopharmacology (Berl); 2012 May; 221(1):155-69. PubMed ID: 22234378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
